Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy

Nabil Dib, Patrick McCarthy, Ann Campbell, Michael Yeager, Francis D. Pagani, Susan Wright, W. Robb MacLellan, Gregg Fonarow, Howard J. Eisen, Robert E. Michler, Philip Binkley, Diane Buchele, Ronald Korn, Marwan Ghazoul, Jonathan Dinsmore, Shaun R. Opie, Edward Diethrich

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Successful autologous skeletal myoblast transplantation into infarcted myocardium in a variety of animal models has demonstrated improvement in cardiac function. We evaluated the safety and feasibility of transplanting autologous myoblasts into infarcted myocardium of patients undergoing concurrent coronary artery bypass grafting (CABG) or left ventricular assist device implantation (LVAD). In addition, we sought to gain preliminary information on graft survival and any potential improvement of cardiac function. Eighteen patients with a history of ischemic cardiomyopathy participated in a phase I, nonrandomized, multicenter pilot study of autologous skeletal myoblast transplantation concurrent with CABG or LVAD implantation. Twelve patients with a history of previous myocardial infarction (MI) and a left ventricular ejection of less than 30% were enrolled in the CABG arm. In a second arm, six patients underwent LVAD implantation as a bridge to heart transplantation and were required to donate their heart for testing at the time of heart transplant. Myoblasts were successfully transplanted in all patients without any acute injection-related complications or significant long-term unexpected adverse events. Follow-up PET scans showed new areas of viability within the infarct scar in CABG patients. Echocardiography measured an average improvement in left ventricular ejection fraction (LVEF) from 25% to 34%. Histological evaluation in four out of five patients who underwent heart transplantation documented survival and engraftment of the skeletal myoblasts within the infarcted myocardium. These interim results demonstrate survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality may offer a potential therapeutic treatment for end-stage heart disease.

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalCell Transplantation
Volume14
Issue number1
StatePublished - 2005
Externally publishedYes

Fingerprint

Autologous Transplantation
Myoblasts
Cardiomyopathies
Left ventricular assist devices
Safety
Skeletal Myoblasts
Ion implantation
Coronary Artery Bypass
Heart-Assist Devices
Myocardium
Heart Transplantation
Echocardiography
Transplants
Arm
Transplantation
Grafts
Survival
Animals
Graft Survival
Positron-Emission Tomography

Keywords

  • Autologous
  • Cell transplantation
  • Myoblast
  • Myocardial infarction

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Dib, N., McCarthy, P., Campbell, A., Yeager, M., Pagani, F. D., Wright, S., ... Diethrich, E. (2005). Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy. Cell Transplantation, 14(1), 11-19.

Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy. / Dib, Nabil; McCarthy, Patrick; Campbell, Ann; Yeager, Michael; Pagani, Francis D.; Wright, Susan; MacLellan, W. Robb; Fonarow, Gregg; Eisen, Howard J.; Michler, Robert E.; Binkley, Philip; Buchele, Diane; Korn, Ronald; Ghazoul, Marwan; Dinsmore, Jonathan; Opie, Shaun R.; Diethrich, Edward.

In: Cell Transplantation, Vol. 14, No. 1, 2005, p. 11-19.

Research output: Contribution to journalArticle

Dib, N, McCarthy, P, Campbell, A, Yeager, M, Pagani, FD, Wright, S, MacLellan, WR, Fonarow, G, Eisen, HJ, Michler, RE, Binkley, P, Buchele, D, Korn, R, Ghazoul, M, Dinsmore, J, Opie, SR & Diethrich, E 2005, 'Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy', Cell Transplantation, vol. 14, no. 1, pp. 11-19.
Dib N, McCarthy P, Campbell A, Yeager M, Pagani FD, Wright S et al. Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy. Cell Transplantation. 2005;14(1):11-19.
Dib, Nabil ; McCarthy, Patrick ; Campbell, Ann ; Yeager, Michael ; Pagani, Francis D. ; Wright, Susan ; MacLellan, W. Robb ; Fonarow, Gregg ; Eisen, Howard J. ; Michler, Robert E. ; Binkley, Philip ; Buchele, Diane ; Korn, Ronald ; Ghazoul, Marwan ; Dinsmore, Jonathan ; Opie, Shaun R. ; Diethrich, Edward. / Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy. In: Cell Transplantation. 2005 ; Vol. 14, No. 1. pp. 11-19.
@article{f59066a3548647f98d5a2c92f6559850,
title = "Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy",
abstract = "Successful autologous skeletal myoblast transplantation into infarcted myocardium in a variety of animal models has demonstrated improvement in cardiac function. We evaluated the safety and feasibility of transplanting autologous myoblasts into infarcted myocardium of patients undergoing concurrent coronary artery bypass grafting (CABG) or left ventricular assist device implantation (LVAD). In addition, we sought to gain preliminary information on graft survival and any potential improvement of cardiac function. Eighteen patients with a history of ischemic cardiomyopathy participated in a phase I, nonrandomized, multicenter pilot study of autologous skeletal myoblast transplantation concurrent with CABG or LVAD implantation. Twelve patients with a history of previous myocardial infarction (MI) and a left ventricular ejection of less than 30{\%} were enrolled in the CABG arm. In a second arm, six patients underwent LVAD implantation as a bridge to heart transplantation and were required to donate their heart for testing at the time of heart transplant. Myoblasts were successfully transplanted in all patients without any acute injection-related complications or significant long-term unexpected adverse events. Follow-up PET scans showed new areas of viability within the infarct scar in CABG patients. Echocardiography measured an average improvement in left ventricular ejection fraction (LVEF) from 25{\%} to 34{\%}. Histological evaluation in four out of five patients who underwent heart transplantation documented survival and engraftment of the skeletal myoblasts within the infarcted myocardium. These interim results demonstrate survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality may offer a potential therapeutic treatment for end-stage heart disease.",
keywords = "Autologous, Cell transplantation, Myoblast, Myocardial infarction",
author = "Nabil Dib and Patrick McCarthy and Ann Campbell and Michael Yeager and Pagani, {Francis D.} and Susan Wright and MacLellan, {W. Robb} and Gregg Fonarow and Eisen, {Howard J.} and Michler, {Robert E.} and Philip Binkley and Diane Buchele and Ronald Korn and Marwan Ghazoul and Jonathan Dinsmore and Opie, {Shaun R.} and Edward Diethrich",
year = "2005",
language = "English (US)",
volume = "14",
pages = "11--19",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "1",

}

TY - JOUR

T1 - Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy

AU - Dib, Nabil

AU - McCarthy, Patrick

AU - Campbell, Ann

AU - Yeager, Michael

AU - Pagani, Francis D.

AU - Wright, Susan

AU - MacLellan, W. Robb

AU - Fonarow, Gregg

AU - Eisen, Howard J.

AU - Michler, Robert E.

AU - Binkley, Philip

AU - Buchele, Diane

AU - Korn, Ronald

AU - Ghazoul, Marwan

AU - Dinsmore, Jonathan

AU - Opie, Shaun R.

AU - Diethrich, Edward

PY - 2005

Y1 - 2005

N2 - Successful autologous skeletal myoblast transplantation into infarcted myocardium in a variety of animal models has demonstrated improvement in cardiac function. We evaluated the safety and feasibility of transplanting autologous myoblasts into infarcted myocardium of patients undergoing concurrent coronary artery bypass grafting (CABG) or left ventricular assist device implantation (LVAD). In addition, we sought to gain preliminary information on graft survival and any potential improvement of cardiac function. Eighteen patients with a history of ischemic cardiomyopathy participated in a phase I, nonrandomized, multicenter pilot study of autologous skeletal myoblast transplantation concurrent with CABG or LVAD implantation. Twelve patients with a history of previous myocardial infarction (MI) and a left ventricular ejection of less than 30% were enrolled in the CABG arm. In a second arm, six patients underwent LVAD implantation as a bridge to heart transplantation and were required to donate their heart for testing at the time of heart transplant. Myoblasts were successfully transplanted in all patients without any acute injection-related complications or significant long-term unexpected adverse events. Follow-up PET scans showed new areas of viability within the infarct scar in CABG patients. Echocardiography measured an average improvement in left ventricular ejection fraction (LVEF) from 25% to 34%. Histological evaluation in four out of five patients who underwent heart transplantation documented survival and engraftment of the skeletal myoblasts within the infarcted myocardium. These interim results demonstrate survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality may offer a potential therapeutic treatment for end-stage heart disease.

AB - Successful autologous skeletal myoblast transplantation into infarcted myocardium in a variety of animal models has demonstrated improvement in cardiac function. We evaluated the safety and feasibility of transplanting autologous myoblasts into infarcted myocardium of patients undergoing concurrent coronary artery bypass grafting (CABG) or left ventricular assist device implantation (LVAD). In addition, we sought to gain preliminary information on graft survival and any potential improvement of cardiac function. Eighteen patients with a history of ischemic cardiomyopathy participated in a phase I, nonrandomized, multicenter pilot study of autologous skeletal myoblast transplantation concurrent with CABG or LVAD implantation. Twelve patients with a history of previous myocardial infarction (MI) and a left ventricular ejection of less than 30% were enrolled in the CABG arm. In a second arm, six patients underwent LVAD implantation as a bridge to heart transplantation and were required to donate their heart for testing at the time of heart transplant. Myoblasts were successfully transplanted in all patients without any acute injection-related complications or significant long-term unexpected adverse events. Follow-up PET scans showed new areas of viability within the infarct scar in CABG patients. Echocardiography measured an average improvement in left ventricular ejection fraction (LVEF) from 25% to 34%. Histological evaluation in four out of five patients who underwent heart transplantation documented survival and engraftment of the skeletal myoblasts within the infarcted myocardium. These interim results demonstrate survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality may offer a potential therapeutic treatment for end-stage heart disease.

KW - Autologous

KW - Cell transplantation

KW - Myoblast

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=20144379387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144379387&partnerID=8YFLogxK

M3 - Article

C2 - 15789658

AN - SCOPUS:20144379387

VL - 14

SP - 11

EP - 19

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 1

ER -